The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | Current treatment landscape for anti-PD-1 resistant advanced melanoma
Barbara Ma, MD, MS, Weill Cornell Medicine, New York, NY, discusses the current treatment landscape for patients with advanced melanoma who progress on anti-PD-1 therapy, highlighting the limited options of immunotherapy, targeted therapy, or chemotherapy. Dr Ma comments on the approval of lifileucel for patients who have progressed on anti-PD-1 therapy and the potential survival benefit of lifileucel based on an indirect comparison adjusting for baseline patient characteristics. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
